The MedicalXpress report accurately captures lipedema's core features—symmetrical fat accumulation resistant to diet, onset at hormonal shifts, and frequent confusion with obesity—but stops short of examining the deeper systemic failures. Observational studies, such as a 2019 cross-sectional analysis in the Journal of Clinical Medicine involving 200 women, reveal that diagnostic delays average 19 years, with 70% initially labeled obese; this small, non-randomized sample highlights selection bias yet consistently points to under-recognition tied to women's pain being dismissed as lifestyle failure. A 2022 review in Plastic and Reconstructive Surgery synthesized genetic data from family pedigrees, noting autosomal dominant patterns without identifying specific loci, underscoring how limited RCT evidence (none large-scale exist due to rarity) leaves treatments like tumescent liposuction reliant on case series showing 50-70% pain reduction but with conflicts from surgical centers promoting the procedure. What coverage misses is the parallel to other female-predominant conditions like endometriosis, where similar hormonal triggers and diagnostic gaps reflect historical underfunding of women's health research—NIH data shows female-specific disorders receive disproportionately less funding per patient. This pattern amplifies mobility decline and secondary lymphedema risks, particularly when obesity co-occurs, demanding integrated care models beyond the source's nuance on exercise. True progress requires gender-sensitive protocols that validate patient history over BMI metrics alone.